Cantor Fitzgerald Issues Negative Outlook for TARA Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA) – Research analysts at Cantor Fitzgerald dropped their FY2025 EPS estimates for shares of Protara Therapeutics in a research report issued on Thursday, March 20th. Cantor Fitzgerald analyst L. Watsek now expects that the company will earn ($1.71) per share for the year, down from their previous forecast of ($1.62). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share.

TARA has been the topic of a number of other reports. Lifesci Capital began coverage on shares of Protara Therapeutics in a report on Tuesday, March 11th. They issued an “outperform” rating and a $22.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price target on shares of Protara Therapeutics in a report on Thursday, March 6th. Finally, Guggenheim reiterated a “buy” rating and set a $20.00 price objective on shares of Protara Therapeutics in a report on Friday, December 6th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Protara Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $22.50.

Protara Therapeutics Trading Up 0.6 %

Shares of NASDAQ:TARA opened at $4.73 on Monday. The company has a market capitalization of $173.91 million, a PE ratio of -1.68 and a beta of 1.69. Protara Therapeutics has a 12-month low of $1.60 and a 12-month high of $10.48. The business’s fifty day simple moving average is $4.27 and its 200-day simple moving average is $3.62.

Protara Therapeutics (NASDAQ:TARA) last released its quarterly earnings data on Wednesday, March 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.09.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC increased its position in shares of Protara Therapeutics by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 179,593 shares of the company’s stock valued at $948,000 after acquiring an additional 9,553 shares during the period. Commonwealth Equity Services LLC raised its stake in shares of Protara Therapeutics by 90.4% in the fourth quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company’s stock worth $195,000 after purchasing an additional 17,572 shares during the last quarter. HBK Investments L P purchased a new stake in Protara Therapeutics in the fourth quarter valued at approximately $106,000. Squarepoint Ops LLC purchased a new stake in shares of Protara Therapeutics in the 4th quarter valued at $110,000. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Protara Therapeutics in the fourth quarter worth $111,000. Hedge funds and other institutional investors own 38.13% of the company’s stock.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.